Contemporary Drug Problems
August 28, 2025
Jason K. Day, Michael Th. Grooff
1 citation
Established by the 1971 United Nations (UN) Convention on Psychotropic Substances, the prohibition of the recreational use of psychedelics (lysergic acid diethylamide [LSD], psilocybin, N , N -dimethyltryptamine [ N , N -DMT], and mescaline) has two premises. First, recreational use poses a serious threat to public health because psychedelics are highly liable to addiction and abuse. Second,...
TIPS - Trends in Pharmacological Sciences
August 28, 2025
Alex C. Kwan, John R. Mantsch, John D. Mccorvy
7 citations
There is growing interest in developing psychedelic-inspired drugs for treating psychiatric disorders. However, identifying next-generation psychedelic analogs with ideal receptor selectivity and true therapeutic efficacy remains a major challenge. Recent progress has been driven by advances in determining agonist-induced biased signal transduction, high-content behavioral phenotyping via...
Pharmaceutical Science
August 27, 2025
Guilllermo Castaño-perez, Sara Isabel Castaño-ocampo
The resurgence of research on the use of psychedelic substances for the treatment of mental disorders and addictions has generated significant interest in the scientific and clinical communities. This chapter examines the current evidence on the efficacy, safety, and limitations of psychedelics in the treatment of these conditions. Studies investigating the use of psychedelics as monotherapy...
Neuroscience of Consciousness
August 26, 2025
S. Tumkaya, Bengü Yücens, Muhammet Gündüz et al.
Abstract Disruption of conscious access contributes to the advent of psychotic symptoms in schizophrenia and could also explain lack of insight in other psychiatric disorders. In this study, we explored how insight and psychotic symptoms related to disruption of consciousness in obsessive-compulsive disorder (OCD) and schizophrenia, respectively. Patients with schizophrenia, and patients with...
Psychedelics
August 26, 2025
Harriet de Wit
Professor Harriet de Wit, a pioneering researcher in psychoactive drugs at the University of Chicago, shares her remarkable 45-year scientific journey in this illuminating Genomic Press Interview. As Director of the Human Behavioral Pharmacology Laboratory and recipient of prestigious honors including the 2019 European Behavioral Pharmacology Society Distinguished Investigator Award, Dr. de Wit...
Journal of Psychopharmacology
August 26, 2025
Emma Robinson
Psychiatric disorders represent a particularly challenging area of medicine to study using non-human animals. They arise from a complex interaction between genetic and environmental factors and are diagnosed using clinical interviews and diagnostic criteria based largely on self-reported symptoms and with significant heterogeneity seen within patient populations. Anxiety and major depressive...
ACS Omega
August 26, 2025
Roman Boča, Juraj Štofko, Cyril Rajnák
Small molecules containing phenyl and aliphatic amine groups belonging to psychotropic drugs were studied by quantum chemical computational methods. Each of the 9 studied species (phenethylamine, amphetamine, ephedrine, pseudoephedrine, methamphetamine, MDMA, MDEA, MDA, MDAI) was considered in three oxidation states: neutral molecule, molecular cation, and molecular anion. Protonated residues...
The FASEB Journal
August 26, 2025
Joshua C. Flowers, Paige E. Vetter, McKennon J. Wiles et al.
7 citations
ABSTRACT Chronic stress affects brain functions, leading to the development of mental disorders like anxiety and depression, as well as cognitive decline and social dysfunction. Among many biological changes in chronically stressed brains, disruptions in AMPA Receptor (AMPAR)‐mediated synaptic transmission in the hippocampus are associated with stress responses. We have revealed that low‐dose...
Postepy psychiatrii neurologii
August 25, 2025
Nikolaos Statharakos, Elisavet Papadopoulou, Aaron J. Alvares et al.
1 citation
Purpose: Psychedelic substances are attracting attention for their therapeutic potential in mental health disorders. Emerging research suggests that even negative psychedelic experiences, or "bad trips," may hold therapeutic potential when managed in controlled settings. This narrative review explores the nature of "bad trips", their contributing factors, and their integration into therapeutic...
August 23, 2025
Joseph M. Diehl, M. Zachary Rosenthal
preprint
Psychedelic-assisted psychotherapy (PAP) has emerged as a promising intervention for conditions such as depression, PTSD, and substance use disorders by enhancing the therapeutic potential of psychedelics with structured psychological support during preparation, dosing, and integration phases. Despite encouraging trial results, evidence for therapeutic mechanisms and optimal frameworks for PAP...